{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041223","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.092944+00:00","generated_at":"2026-06-08T04:02:44.645220+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi Biotherapeutics reports Q3 net loss of $2.0M; cash increases to $10.1M after business combination","bullets":["Net loss of $2.0M ($0.14 per share) for Q3 2023 versus $5.4M loss ($0.63 per share) for Q3 2022.","R&D expenses rose to $3.3M from $1.9M; G&A decreased to $4.0M from $5.0M.","Cash and restricted cash of $10.3M as of Sept 30, 2023, versus $0.6M at Dec 31, 2022, reflecting business combination.","First patient dosed by City of Hope in Phase 1 trial of CLD-101 for recurrent high-grade glioma; interim data expected 1H2024.","Appointed Andrew Jackson as CFO and Alan Stewart to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041223","json":"https://secwatch.observer/filing/0001493152-23-041223.json","markdown":"https://secwatch.observer/filing/0001493152-23-041223.md","text":"https://secwatch.observer/filing/0001493152-23-041223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/0001493152-23-041223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:02:44.645220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffa1cce0e06e88aa7b782c51eb3c4e9f0f527cd4","claim":"Calidi Biotherapeutics, Inc. reported third quarter 2023 results: net income $2.0 million, or $0.14 per share, EPS $0.14 per share.","evidence_excerpt":"The company reported a net loss of $2.0 million, or $0.14 per share, for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223041223/0001493152-23-041223-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"$2.0 million, or $0.14 per share"},{"label":"EPS","value":"$0.14 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}